Suven Life Sciences Limited (BOM:530239)

Market Cap	30.37B
Revenue (ttm)	58.63M
Net Income (ttm)	-2.12B
Shares Out	227.47M
EPS (ttm)	-9.63
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,315
Average Volume	17,002
Open	135.35
Previous Close	135.25
Day's Range	135.00 - 143.70
52-Week Range	102.70 - 303.00
Beta	0.36
RSI	26.03
Earnings Date	Jan 29, 2026

About Suven Life Sciences

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a histamine 3 recepto...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1989
• Employees: 138
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 530239

Financial Performance

In 2024, Suven Life Sciences's revenue was 66.56 million, a decrease of -43.08% compared to the previous year's 116.93 million. Losses were -1.61 billion, 53.0% more than in 2023.